Coulter Partners top hires for VC & PE portfolio companies Q1-2024

Search Highlights

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.

This quarter’s successful placements include:
• CEO, Therapeutic devices, Austria
• Chief Business Officer, Precision biologics, US
• Chief Financial Officer, Remote monitoring, France
• Chief Strategy Officer, Medical devices, Israel
• Chief Medical Officer, Radiopharmaceuticals, US
• Chief of Staff, Vaccines, Denmark
• VP Global Program Leader, Respiratory, Multi-modality biotech, UK
• VP Technology & Product Development, DNA technology, UK
• Controller, Contract manufacturing, US
• Senior Director Pharmaceutical Development , Drug delivery, Ireland
• Director Market Access & Pricing Global, Ophthalmology, Italy
• Investment Manager Digital Health, Life sciences investor, Netherlands
• General Manager Infectious Diseases, Biocluster, France
• Board Director, Personalized digital health, Switzerland
• Board Director, Electronic medical instrumentation, US
• Board Director, Immunotherapies, Sweden

Newly opened projects include:
• CEO, Medical devices, Belgium
• CEO, Precision medicines, US
• Chief Commercial Officer, Contract research organization (CRO), UK
• Chief Development Officer, Protein degradation, DACH
• Chief Scientific Officer, Small molecules, Spain
• Chief Financial Officer, Gene therapy, US
• Chief Operating Officer, Incubator/ tech transfer, UK
• Head of Strategy & Commercial Excellence, Drug delivery systems, Germany
• SVP, Head of Business Development, Drug discovery services, Germany
• VP of Science, Precision nutrition, UK
• VP, Head of Translational Development, Gene editing, Spain
• VP Research & Preclinical, Synthetic biology , UK
• VP Business Development, tRNA technologies, US
• Life Sciences Partner, Life sciences investor, Italy
• Board Director, T-cell therapies, US/ Europe

More within